AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31021886 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg intravenous dexamethasone before incision
Number of subjects: 160
Study 31021886 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg oral pregabalin 1 hour before surgery
Number of subjects: 160
Study 31021886 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.2 mg/kg intravenous dexamethasone and 150 mg oral pregabalin
Number of subjects: 160
Study 31021886 — intervention group
Group type: COMPARATOR
Intervention: None of the above (control)
Number of subjects: 160
Study 27568165 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity (n=818) consisting of aerobic, resistance, and flexibility exercises performed both center-based (2 times/week) and home-based (3-4 times/week) sessions
Number of subjects: 1635
Study 27568165 — intervention group
Group type: COMPARATOR
Intervention: Health education program (n=817) consisting of weekly to monthly workshops covering relevant health information
Number of subjects: 1635
Study 26763225 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitors (ICM)
Number of subjects: 441
Study 26763225 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 441
Study 24509399 — intervention group
Group type: EXPERIMENTAL
Intervention: AAI-guided anaesthesia
Number of subjects: 450
Study 24509399 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinical signs only)
Number of subjects: 450
Study 22488770 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (Gd‐BOPTA) 0.15 mmol/kg
Number of subjects: 20
Study 22488770 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (Gd‐DTPA) 0.15 mmol/kg
Number of subjects: 20
Study 19175935 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I - progressive resistance exercises (PRE) + functionally-oriented exercises (FOE) + nutritional supplementation (NS)
Number of subjects: 91
Study 19175935 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II - PRE + FOE + placebo
Number of subjects: 91
Study 19175935 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III - standard exercises (SE) + FOE + NS
Number of subjects: 91
Study 19175935 — intervention group
Group type: EXPERIMENTAL
Intervention: Group IV - SE + FOE + placebo
Number of subjects: 91
Study 17289886 — intervention group
Group type: EXPERIMENTAL
Intervention: CellSearch system (Veridex, Warren, NJ)
Number of subjects: 92
Study 16135479 — intervention group
Group type: EXPERIMENTAL
Intervention: 66 Gy in 33 fractions over 45 days (long arm)
Number of subjects: 936
Study 16135479 — intervention group
Group type: COMPARATOR
Intervention: 52.5 Gy in 20 fractions over 28 days (short arm)
Number of subjects: 936
Study 16135479 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 936
Study 11359222 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroporation (EP) with 4%, 10%, or 20% lidocaine
Number of subjects: 10
Study 11359222 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroporation (EP)
Number of subjects: 10
Study 11359222 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroincorporation (EI)
Number of subjects: 10
Study 11359222 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis (IP)
Number of subjects: 10
Study 11359222 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 10
Study 9274835 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF) in conjunction with ciclosporin and steroids
Number of subjects: 3
Study 9274835 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin and steroids
Number of subjects: 3
Study 9274835 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Number of subjects: 3
Study 7876400 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. torsemide
Number of subjects: 19
Study 7876400 — intervention group
Group type: COMPARATOR
Intervention: i.v. furosemide
Number of subjects: 19
Study 3724121 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosyllabic adaptive speech test (MAST) procedures
Number of subjects: 60
Study 3724121 — intervention group
Group type: COMPARATOR
Intervention: Different randomization of the same speech stimuli presented at a constant level, equal to their MAST threshold
Number of subjects: 60
Study 3724121 — intervention group
Group type: EXPERIMENTAL
Intervention: MAST threshold procedure
Number of subjects: 60
Study 3724121 — intervention group
Group type: EXPERIMENTAL
Intervention: MAST thresholds
Number of subjects: 60
Study 29291623 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity Score Analysis (PSA) based on pretest and demographic covariates
Number of subjects: 0
Study 29291623 — intervention group
Group type: COMPARATOR
Intervention: Randomized study of a pre-K math curriculum
Number of subjects: 0
Study 26527239 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive thrombus aspiration (TA) using 7F devices or a catheter/artery ratio >0.6
Number of subjects: 76
Study 26527239 — intervention group
Group type: COMPARATOR
Intervention: Conservative thrombus aspiration (TA) using 6F devices or a catheter/artery ratio ≤0.6
Number of subjects: 76
Study 24886488 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily in addition to routine care
Number of subjects: 2616
Study 24886488 — intervention group
Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 2616
Study 23570952 — intervention group
Group type: EXPERIMENTAL
Intervention: Various antidepressants and augmentation strategies including extended-release venlafaxine, mitazapine, paroxetine, risperidone, sodium valproate, buspirone, trazodone, thyroid hormone augmenting to paroxetine
Number of subjects: 375
Study 21345603 — intervention group
Group type: EXPERIMENTAL
Intervention: Rearing system 1
Number of subjects: 61
Study 21345603 — intervention group
Group type: EXPERIMENTAL
Intervention: Rearing system 2
Number of subjects: 61
Study 21345603 — intervention group
Group type: EXPERIMENTAL
Intervention: Rearing system 3
Number of subjects: 61
Study 21345603 — intervention group
Group type: COMPARATOR
Intervention: All rearing systems
Number of subjects: 61
Study 18805603 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (clindamycin‐BPO 2.5%)
Number of subjects: 2813
Study 18805603 — intervention group
Group type: COMPARATOR
Intervention: Individual active ingredients
Number of subjects: 2813
Study 18805603 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 2813
Study 17121727 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine combined with fentanyl (KF group)
Number of subjects: 80
Study 17121727 — intervention group
Group type: COMPARATOR
Intervention: Exclusive use of fentanyl (FT group)
Number of subjects: 80
Study 12857557 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V Leiden mutation
Number of subjects: 50
Study 12857557 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor II A20210 mutation
Number of subjects: 50
Study 12857557 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-eclampsia (PE)
Number of subjects: 50
Study 11143865 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 0
Study 11143865 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine
Number of subjects: 0
Study 9433391 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg once a day for 5 days
Number of subjects: 8
Study 9433391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1531972 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 82
Study 1531972 — intervention group
Group type: COMPARATOR
Intervention: Clodronate
Number of subjects: 82
Study 6806060 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg cimetidine in the evening (group A)
Number of subjects: 66
Study 6806060 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg cimetidine both morning and evening (group B)
Number of subjects: 66
Study 6806060 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group C)
Number of subjects: 66
Study 6806060 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups A and B (treated)
Number of subjects: 66
Study 6806060 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 66
Study 6806060 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smokers
Number of subjects: 66
Study 30523032 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 34
Study 30523032 — intervention group
Group type: COMPARATOR
Intervention: Adjustable gastric banding (AGB)
Number of subjects: 34
Study 30523032 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) with exendin(9-39) infusion
Number of subjects: 34
Study 29702716 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 164
Study 29702716 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 164
Study 26551044 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG AFL‐PDT (single session, n = 20)
Number of subjects: 39
Study 26551044 — intervention group
Group type: COMPARATOR
Intervention: MAL‐PDT (two sessions, 7 days apart, n = 19)
Number of subjects: 39
Study 26551044 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG AFL‐PDT
Number of subjects: 39
Study 26551044 — intervention group
Group type: COMPARATOR
Intervention: MAL‐PDT
Number of subjects: 39
Study 26551044 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG AFL‐PDT and MAL‐PDT
Number of subjects: 39
Study 24315907 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg morphine intravenously
Number of subjects: 24
Study 21390540 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (Project EXPLORE), details on dosage and duration not specified.
Number of subjects: 0
Study 21390540 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-Latino MSM), details on intervention not specified.
Number of subjects: 0
Study 19709634 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment
Number of subjects: 0
Study 19709634 — intervention group
Group type: COMPARATOR
Intervention: Naloxone administration
Number of subjects: 0
Study 17482439 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine needle aspiration coupled with real-time PCR
Number of subjects: 21
Study 16880099 — intervention group
Group type: EXPERIMENTAL
Intervention: ccTGA
Number of subjects: 13
Study 16880099 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study 14691993 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotaped recording of the consultation
Number of subjects: 117
Study 14691993 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-technical letter
Number of subjects: 117
Study 14691993 — intervention group
Group type: COMPARATOR
Intervention: Standard information (control group)
Number of subjects: 117
Study 9890612 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk from mothers of infants with cow milk allergy
Number of subjects: 60
Study 9890612 — intervention group
Group type: COMPARATOR
Intervention: Breast milk from mothers of healthy infants
Number of subjects: 60
Study 9890612 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk from mothers with cow milk allergic infants
Number of subjects: 60
Study 9890612 — intervention group
Group type: COMPARATOR
Intervention: Breast milk from mothers with healthy infants
Number of subjects: 60
Study 8994201 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with complete callosal defect (one acquired and one congenital)
Number of subjects: 0
Study 8994201 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study 1897469 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potassium diet (163 +/- 9 mmol potassium/d) with potassium load (50 mmol)
Number of subjects: 8
Study 1897469 — intervention group
Group type: COMPARATOR
Intervention: Low-potassium diet (69 +/- 2 mmol potassium/d) with placebo
Number of subjects: 8
Study 1897469 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic potassium intake
Number of subjects: 8
Study 1897469 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute potassium intake
Number of subjects: 8
Study 7049307 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg on the day of operation and for the following 2 days)
Number of subjects: 166
Study 7049307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 31487406 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg (T100)
Number of subjects: 1862
Study 31487406 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg (T200)
Number of subjects: 1862
Study 31487406 — intervention group
Group type: COMPARATOR
Intervention: Tildrakizumab 100 mg (T100) with placebo (PBO)
Number of subjects: 1862
Study 31487406 — intervention group
Group type: COMPARATOR
Intervention: Tildrakizumab 200 mg (T200) with placebo (PBO)
Number of subjects: 1862
Study 31487406 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) switching to Tildrakizumab 200 mg (ETN/T200)
Number of subjects: 1862
Study 31487406 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab (T100/T100 or T200/T200)
Number of subjects: 1862
Study 31487406 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab (T100/T200 or T200/T100)
Number of subjects: 1862
Study 29756262 — intervention group
Group type: COMPARATOR
Intervention: Reduced serving sizes (by 25%) of alcohol in study 1
Number of subjects: 278
Study 29756262 — intervention group
Group type: COMPARATOR
Intervention: Reduced serving sizes (by 28.6-33.3%) of alcohol in study 2
Number of subjects: 278
Study 29756262 — intervention group
Group type: COMPARATOR
Intervention: Decreasing the serving size of on-trade alcoholic beverages by 25%
Number of subjects: 278
Study 29122000 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot-care awareness program for 6 months
Number of subjects: 11
Study 29122000 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 11
Study 26711976 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI) cystoscopy assisted holmium laser resection (HoLRBt)
Number of subjects: 124
Study 26711976 — intervention group
Group type: COMPARATOR
Intervention: White light imaging transurethral resection (WLI-TURBt)
Number of subjects: 124
Study 24122669 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (A-L)
Number of subjects: 186
Study 24122669 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine-sulfadoxine-pyrimethamine (AQ-SP)
Number of subjects: 186
Study 24122669 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (AQ-AS)
Number of subjects: 186
Study 21615951 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving therapy, regular written communication, patient support, cultural assessment, improved access to primary care, risk management strategy
Number of subjects: 0
Study 21615951 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (treatment as usual)
Number of subjects: 0
Study 18305265 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vasopressin (0.01 to 0.03 U per minute)
Number of subjects: 778
Study 18305265 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (5 to 15 microg per minute)
Number of subjects: 778
Study 18305265 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vasopressin (0.01 to 0.03 U per minute) in less severe septic shock
Number of subjects: 778
Study 18305265 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (5 to 15 microg per minute) in less severe septic shock
Number of subjects: 778
Study 18305265 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vasopressin (0.01 to 0.03 U per minute) in more severe septic shock
Number of subjects: 778
Study 18305265 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (5 to 15 microg per minute) in more severe septic shock
Number of subjects: 778
Study 15945499 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT)
Number of subjects: 56
Study 15945499 — intervention group
Group type: COMPARATOR
Intervention: Control group (appropriate medications)
Number of subjects: 56
Study 12946968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic muscle training (n = 135)
Number of subjects: 393
Study 12946968 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (n = 128)
Number of subjects: 393
Study 12946968 — intervention group
Group type: COMPARATOR
Intervention: Ordinary activity (control group; n = 130)
Number of subjects: 393
Study 12946968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic muscle training and relaxation training
Number of subjects: 393
Study 10784270 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic medicine
Number of subjects: 126
Study 10784270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 10784270 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 126
Study 8578059 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (900 to 1800 mg/day)
Number of subjects: 705
Study 8578059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705
Study 2054316 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 120 mg/m2 i.v. push every 21 days pre-operatively, and four additional courses post-operatively (group I)
Number of subjects: 71
Study 2054316 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery (group II)
Number of subjects: 71
Study 2054316 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathological study of resected specimens after initial chemotherapy
Number of subjects: 71
Study 6132645 — intervention group
Group type: EXPERIMENTAL
Intervention: Distigmine bromide (Ubretid)
Number of subjects: 93
Study 6132645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 31039099 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day recall questions
Number of subjects: 515
Study 31039099 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day recall questions
Number of subjects: 515
Study 31039099 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day and 30-day recall questions
Number of subjects: 515
Study 27510741 — intervention group
Group type: COMPARATOR
Intervention: Standard group (brief advance directive form)
Number of subjects: 316
Study 27510741 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded group (brief, expanded, or comprehensive form)
Number of subjects: 316
Study 26727117 — intervention group
Group type: EXPERIMENTAL
Intervention: REFIT weight loss program
Number of subjects: 107
Study 26727117 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 107
Study 24892115 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional oral hygiene procedures (1 hour session)
Number of subjects: 40
Study 24892115 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 hour in the waiting room)
Number of subjects: 40
Study 22640463 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning module on leukaemia
Number of subjects: 0
Study 22640463 — intervention group
Group type: COMPARATOR
Intervention: Existing online resources (Control)
Number of subjects: 0
Study 19571597 — intervention group
Group type: EXPERIMENTAL
Intervention: sertraline plus atomoxetine
Number of subjects: 276
Study 19571597 — intervention group
Group type: COMPARATOR
Intervention: sertraline plus placebo
Number of subjects: 276
Study 19571597 — intervention group
Group type: EXPERIMENTAL
Intervention: sertraline
Number of subjects: 276
Study 17890427 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone therapy for 12 weeks
Number of subjects: 23
Study 15375799 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone (30 mg/d)
Number of subjects: 45
Study 15375799 — intervention group
Group type: COMPARATOR
Intervention: glibenclamide (5 mg/d)
Number of subjects: 45
Study 15375799 — intervention group
Group type: COMPARATOR
Intervention: voglibose (0.6 mg/d)
Number of subjects: 45
Study 15375799 — intervention group
Group type: COMPARATOR
Intervention: control group (age-matched healthy subjects, n = 30)
Number of subjects: 45
Study 11349391 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 0
Study 11349391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9133509 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 517
Study 9133509 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulant therapy
Number of subjects: 517
Study 8054013 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 8400
Study 3615589 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-degree posterior inclination
Number of subjects: 13
Study 3615589 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-degree anterior inclination
Number of subjects: 13
Study 3615589 — intervention group
Group type: COMPARATOR
Intervention: 30 degrees and 15 degrees posterior inclination
Number of subjects: 13
Study 28983071 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-oriented language package ('100% organic,' 'all natural' or 'no additives')
Number of subjects: 801
Study 28983071 — intervention group
Group type: COMPARATOR
Intervention: Traditional marketing language package ('fine quality,' 'premium blend' or '100% original')
Number of subjects: 801
Study 27143662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted protease inhibitor monotherapy (PI-monotherapy)
Number of subjects: 146
Study 27143662 — intervention group
Group type: COMPARATOR
Intervention: Standard combination ART (OT group)
Number of subjects: 146
Study 27143662 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic neurocognitive impairment
Number of subjects: 146
Study 24716628 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 379
Study 24716628 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI-1
Number of subjects: 379
Study 24716628 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 379
Study 24716628 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 379
Study 24716628 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin, PAI-1, hsCRP
Number of subjects: 379
Study 23741071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganitumab plus gemcitabine
Number of subjects: 0